Lookup NU author(s): Chrysoula Leontiou,
Professor Jeremy Lakey,
Professor Robert Lightowlers,
Professor Caroline Austin
Full text for this publication is not currently held within this repository. Alternative links are provided below where available.
The anti cancer drug methyl N-(4′-(9-acridinylamino)-3-methoxy- phenyl) methane sulfonamide (mAMSA) targets human DNA topoisomerase IIβ. We report here the first selection with mAMSA of resistant human topoisomerase IIβ. Random mutagenesis of human DNA topoisomerase IIβ cDNA, followed by selection in yeast for resistance to mAMSA, identified βP732L. This mutant was 10-fold less sensitive to mAMSA and cross-resistant to other chemotherapeutic agents such as etoposide, ellipticine, methyl N-(4′-(9-acridinylamino)-2-methoxy-phenyl) carbamate hydrochloride (mAMCA), methyl N-(4′-(9-acridinylamino)-phenyl) carbamate hydrochloride (AMCA), and doxorubicin. βP732L is functional but has reduced strand passage activities and altered DNA binding compared with the wild-type protein. It has drastically altered cleavage properties compared with the wild-type enzyme. It cleaved a 40-base pair (bp) DNA substrate in the presence of magnesium but at positions different from that of the wild-type protein. More striking is that βP732L was unable to cleave the 40-bp DNA substrate, a 500-bp linear substrate, or a 4.3-kilobase supercoiled substrate in the presence of calcium ions. This is the first report of a topoisomerase II mutation abolishing the ability of calcium to support DNA cleavage. This provides evidence for metal ion requirement for the phosphoryltransfer reaction of topoisomerase II and a possible mechanism for drug resistance. Copyright © 2006 The American Society for Pharmacology and Experimental Therapeutics.
Author(s): Leontiou C, Lakey JH, Lightowlers R, Turnbull RM, Austin CA
Publication type: Article
Publication status: Published
Journal: Molecular Pharmacology
ISSN (print): 0026-895X
ISSN (electronic): 1521-0111
Publisher: American Society for Pharmacology and Experimental Therapeutics
PubMed id: 16239602
Altmetrics provided by Altmetric